ORAPRED Drug Patent Profile
When do Orapred patents expire, and when can generic versions of Orapred launch?
Orapred is a drug marketed by Concordia Pharms Inc and Advanz Pharma and is included in two NDAs.
The generic ingredient in ORAPRED is prednisolone sodium phosphate. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Orapred
A generic version of ORAPRED was approved as prednisolone sodium phosphate by BAUSCH AND LOMB INC on July 29th, 1994.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORAPRED?
- What are the global sales for ORAPRED?
- What is Average Wholesale Price for ORAPRED?
Summary for ORAPRED
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 8 |
| Patent Applications: | 7,323 |
| Drug Prices: | Drug price information for ORAPRED |
| What excipients (inactive ingredients) are in ORAPRED? | ORAPRED excipients list |
| DailyMed Link: | ORAPRED at DailyMed |
Recent Clinical Trials for ORAPRED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chulalongkorn University | N/A |
| University of Florida | Phase 4 |
| University of California, San Francisco | Phase 4 |
US Patents and Regulatory Information for ORAPRED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia Pharms Inc | ORAPRED | prednisolone sodium phosphate | SOLUTION;ORAL | 075117-001 | Dec 14, 2000 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Advanz Pharma | ORAPRED ODT | prednisolone sodium phosphate | TABLET, ORALLY DISINTEGRATING;ORAL | 021959-003 | Jun 1, 2006 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Advanz Pharma | ORAPRED ODT | prednisolone sodium phosphate | TABLET, ORALLY DISINTEGRATING;ORAL | 021959-001 | Jun 1, 2006 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Advanz Pharma | ORAPRED ODT | prednisolone sodium phosphate | TABLET, ORALLY DISINTEGRATING;ORAL | 021959-002 | Jun 1, 2006 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
